Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761962 | 0.89 | POLB (0.46) | KMT2AMAPTPKMALDH1A1MEN1 | |
| SCHEMBL7434831 | 0.84 | KMT2A (0.48) | CYP3A4CYP2C19KMT2AMAPTPKM | |
| SCHEMBL7599077 | 0.83 | HCRTR1 (0.40) | MAPTPKMALDH1A1TP53CTSK | |
| SCHEMBL7633224 | 0.81 | CTSK (0.56) | CTSK | |
| SCHEMBL4924362 | 0.81 | CTSK (0.56) | CTSK | |
| SCHEMBL5093142 | 0.80 | CTSK (0.47) | CYP3A4CYP2C19KMT2AMAPTALDH1A1 | |
| SCHEMBL5092610 | 0.80 | CTSK (0.40) | CTSK | |
| SCHEMBL5099202 | 0.80 | KMT2A (0.43) | CYP3A4CYP2C19KMT2AMAPTPKM | |
| SCHEMBL6590970 | 0.79 | CTSK (0.41) | MAPTALDH1A1CTSKGAA | |
| SCHEMBL7434825 | 0.79 | KMT2A (0.45) | CYP3A4CYP2C19KMT2AMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CYP3A4 604/4885CYP2C19 626/4885KMT2A 2920/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CYP3A4 604/4885CYP2C19 626/4885KMT2A 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.